Orchestra BioMed (OBIO) Insider David Pacitti Buys 21,277 Shares

David Pacitti Buys Shares of Orchestra BioMed Holdings

On June 23, 2026, David Pacitti acquired 21,277 shares of Orchestra BioMed Holdings, Inc. (NasdaqGM: OBIO). This transaction was part of a wider group filing where multiple leaders added to their holdings on the exact same date, pointing to shared interest among the company's insiders.

Insider Buying and Selling at Orchestra BioMed Holdings, Inc.

The purchase by Pacitti arrived alongside several other notable insider transactions processed on June 23, 2026. John Mack picked up 34,653 shares, while Jason Aryeh and Chris Cleary each bought 42,553 shares. In addition, Pamela Ann Connealy acquired 17,327 shares on that day. These parallel moves show multiple key figures expanding their personal stakes in the biomedical company all at once.

Stock Performance and Recent Trading

Shares of Orchestra BioMed recently traded around $3.90, sitting in a 52-week trading window that spans from a low of $2.20 up to a high of $6.30. The company carries a market capitalization of roughly $375.66 million. Its share price rests below its 50-day moving average of $4.72, though it remains above its 200-day moving average of $4.33.

Analysts Set New Price Targets

Wall Street firms have kept a close watch on the biotech firm, adjusting their targets over the summer and fall. On August 11, 2026, Piper Sandler reiterated an overweight rating on the stock while lifting its price target to $10.00 from $9.00. Later, on September 10, 2026, BTIG upgraded the stock to a buy rating with a $10.00 target. Shortly after, on September 15, 2026, B. Riley Securities maintained a buy rating while raising its target to $11.00 from $10.00. Overall, the stock holds a consensus recommendation of strong buy, supported by seven analyst opinions and a mean price target of $12.14.

What Orchestra BioMed Does

Orchestra BioMed Holdings, Inc. operates as a clinical-stage biomedical company based in New Hope, Pennsylvania. It develops therapeutic candidates for cardiovascular diseases, including its Atrioventricular Interval Modulation therapy and the Virtue Sirolimus AngioInfusion Balloon for treating artery disease. The firm works alongside major medical device partners to advance its clinical pipeline.

Looking Ahead for OBIO

Investors are keeping track of upcoming financial disclosures and corporate milestones for the healthcare firm. The company's next earnings report is expected around November 5, 2026. These insider filings offer a clear look at how executives manage their personal holdings over time.